Onxeo SA Announces New Preclinical Data Confirm the Ability of Asidna to Tackle the Drug-Tolerant Persister Cells and Prevent Tumor Resistance in Several Combination Treatments
December 08, 2021 at 12:00 pm EST
Onxeo SA announced the presentation of new preclinical data confirming the differentiated antitumoral properties of AsiDNATM, its first- in-class DNA Damage Response (DDR) inhibitor, in poster and oral sessions during the EACR-AstraZeneca Virtual Conference organized by the European Association for Cancer Research and AstraZeneca on the theme of Drug Tolerant Persister Cells. Several studies have shown that a small population of tumor cells, treated by targeted therapies, evade cell death by entering a reversible dormancy state known as the Drug-tolerant persister (DTP) state. These DTP cells are identified as major source of targeted therapy failures, thus leading to cancer relapse.